Oncology Venture Sweden Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 6


  • Latest Deal Type
  • M&A

Oncology Venture Sweden General Information


Oncology Venture Sweden AB develops oncology products to improve the efficacy of the drugs and the response rate in cancer patients. The company's products in pipeline include APO010 and Irofulven.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Primary Office
  • Venlighedsvej 1
  • DK-2970 Horsholm
  • Denmark
+45 21 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncology Venture Sweden Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 24-Aug-2018 00.000 Completed Profitable
3. IPO 17-Sep-2015 00.000 00.000 Completed Generating Revenue
2. Early Stage VC 24-Feb-2015 $944K $1.46M Completed Generating Revenue
1. Seed Round 19-Feb-2015 $514K $514K Completed Startup
To view Oncology Venture Sweden’s complete valuation and funding history, request access »

Oncology Venture Sweden Executive Team (4)

Name Title Board Seat Contact Info
Peter Jensen MD Chief Executive Officer
You’re viewing 1 of 4 executive team members. Get the full list »

Oncology Venture Sweden Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial